Literature DB >> 28403727

High-risk human papillomavirus types in HIV-infected and HIV-uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination.

Joyce N Mbatha1,2, Myra Taylor3, Elisabeth Kleppa4,5, Kristine Lillebo4, Hashini N Galappaththi-Arachchige4,5, Deepak Singh6, Eyrun F Kjetland3,4,5, Marc F D Baay4,7, Zilungile L Mkhize-Kwitshana1,8.   

Abstract

BACKGROUND: High-risk human papillomavirus (hr-HPV) infections and low-grade squamous intraepithelial lesions occur frequently in young women. The available vaccines cover up to seven hr-HPV genotypes (HPV16, HPV18, HPV31, HPV33, HPV45, HPV52 and HPV58) and two low-risk HPV types (HPV6 and HPV11). The objective of this study was to describe the hr-HPV genotypes present among HIV-uninfected and HIV-infected young women in rural high schools.
METHODS: Cervicovaginal lavages were obtained from sexually active young women recruited from high schools in KwaZulu-Natal (n = 1223). HPV testing was done by the polymerase chain reaction using GP5+/GP6 + primers and enzyme immunoassay. HIV testing was done using rapid test kits.
RESULTS: Of the 1223 cervicovaginal lavages, 301 (25%) were positive for hr-HPV. The HPV prevalence was higher in HIV infected (32.20%, 95% CI: 0.27-0.38) than in HIV-uninfected women (22.50%, 95% CI: 0.21-0.26), (p = .001). Similarly, multiple infections were slightly more common in HIV infected (59.32%) than in HIV-uninfected women (53.51%), (p = .37). The nine predominant genotypes in descending order were HPV types 16 (n = 99, 22.10%), 51 (n = 58, 12.91%), 18 (n = 56, 12.50%), 35 (n = 50, 11.10%), 33 (n = 47, 10.82%), 56 (n = 42, 9.31%), 45 (n = 34, 7.60%), 52 (n = 32, 7.14%) and 59 (n = 31, 6.91%). HPV 35, 51, 56 and 59 (40.62%), which are not covered by any vaccine, were among the most prevalent in the schools of KwaZulu-Natal.
CONCLUSION: Four of the most predominant high-risk HPV types in this region are not covered by the new nine-valent HPV vaccine.

Entities:  

Keywords:  Human papillomavirus; cervical cancer; human immunodeficiency virus

Mesh:

Substances:

Year:  2017        PMID: 28403727     DOI: 10.1080/23744235.2017.1312513

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  5 in total

Review 1.  Cancer in adolescents and young adults living with HIV.

Authors:  Julia Bohlius; Caroline Foster; Gita Naidu; Mazvita Sengayi; Anna Turkova
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

2.  Be legally wise: When is parental consent required for adolescents' access to pre-exposure prophylaxis (PrEP)?

Authors:  Ann Strode; Catherine M Slack; Zaynab Essack; Jacintha D Toohey; Linda-Gail Bekker
Journal:  South Afr J HIV Med       Date:  2020-11-10       Impact factor: 2.744

3.  Prevalence, risk factors, and pregnancy outcomes of cervical cell abnormalities in the puerperium in a hyperendemic HIV setting.

Authors:  Hopolang C Maise; Dhayendre Moodley; Motshedisi Sebitloane; Suzanne Maman; Benn Sartorius
Journal:  Int J Gynaecol Obstet       Date:  2017-10-23       Impact factor: 3.561

4.  High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N'Djamena, Chad.

Authors:  Ralph-Sydney Mboumba Bouassa; Zita Aleyo Nodjikouambaye; Damtheou Sadjoli; Chatté Adawaye; Hélène Péré; David Veyer; Mathieu Matta; Leman Robin; Serge Tonen-Wolyec; Ali Mahamat Moussa; Donato Koyalta; Laurent Belec
Journal:  PLoS One       Date:  2019-06-03       Impact factor: 3.240

Review 5.  Prevalence and distribution of selected cervical human papillomavirus types in HIV infected and HIV uninfected women in South Africa, 1989-2021: A narrative review.

Authors:  Rixongile R Rikhotso; Emma M Mitchell; Daniel T Wilson; Aubrey Doede; Nontokozo D Matume; Pascal O Bessong
Journal:  S Afr J Infect Dis       Date:  2022-06-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.